This HTML5 document contains 42 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n10http://linked.opendata.cz/resource/drugbank/drug/DB04903/identifier/chemspider/
n13http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n7http://linked.opendata.cz/resource/drugbank/drug/DB04903/identifier/wikipedia/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n8http://linked.opendata.cz/resource/drugbank/drug/DB04903/identifier/pubchem-compound/
n4http://linked.opendata.cz/resource/drugbank/property/
n9http://linked.opendata.cz/resource/drugbank/drug/DB04903/identifier/pubchem-substance/
xsdhhttp://www.w3.org/2001/XMLSchema#
n11http://linked.opendata.cz/resource/drugbank/drug/DB04903/identifier/drugbank/

Statements

Subject Item
n2:DB04903
rdf:type
n3:Drug
n3:description
Pagoclone is an anxiolytic drug from the cyclopyrrolone family, which is related to other more well known drugs such as the sleeping medication zopiclone. It is one of a relatively recently developed class of medicines known as the nonbenzodiazepines, which have similar effects to the older benzodiazepine group, but with quite different chemical structures.
n3:generalReferences
# de Wit H, Vicini L, Haig GM, Hunt T, Feltner D: Evaluation of the abuse potential of pagoclone, a partial GABAA agonist. J Clin Psychopharmacol. 2006 Jun;26(3):268-73. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16702891 # Atack JR, Pike A, Marshall G, Stanley J, Lincoln R, Cook SM, Lewis RT, Blackaby WP, Goodacre SC, McKernan RM, Dawson GR, Wafford KA, Reynolds DS: The in vivo properties of pagoclone in rat are most likely mediated by 5'-hydroxy pagoclone. Neuropharmacology. 2006 May;50(6):677-89. Epub 2006 Jan 20. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16430927 # Bateson A: Pagoclone Indevus. Curr Opin Investig Drugs. 2003 Jan;4(1):91-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12625036 # Sandford JJ, Forshall S, Bell C, Argyropoulos S, Rich A, D'Orlando KJ, Gammans RE, Nutt DJ: Crossover trial of pagoclone and placebo in patients with DSM-IV panic disorder. J Psychopharmacol. 2001 Sep;15(3):205-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11565630
n3:group
investigational
n3:indication
For the potential treatment of panic and anxiety disorders.
owl:sameAs
n13:DB04903
dcterms:title
Pagoclone
adms:identifier
n7:Pagoclone n8:131664 n9:10242921 n10:116335 n11:DB04903
n3:mechanismOfAction
Pagoclone is a subtype-selective drug which binds primarily to the alpha2/alpha3 subtypes of the GABAA receptor which are responsible for the anti-anxiety effects of these kind of drugs, but has relatively little efficacy at the alpha1 subtype which produces the sedative and memory loss effects.
n3:IUPAC-Name
n4:271B5E39-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B5E3F-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B5E3E-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B5E3B-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B5E3C-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B5E3D-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B5E37-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B5E35-363D-11E5-9242-09173F13E4C5 n4:271B5E38-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B5E36-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B5E45-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B5E46-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B5E40-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B5E41-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B5E43-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B5E42-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B5E44-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
133737-32-3
n3:category
n3:Bioavailability
n4:271B5E4B-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B5E4D-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B5E4E-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B5E4A-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B5E49-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B5E4C-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B5E3A-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B5E47-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B5E48-363D-11E5-9242-09173F13E4C5